Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2708-2715

  Kreimer, Aimee R ^a   Johansson, Mattias ^c   Waterboer, Tim ^d   Kaaks, Rudolf ^d   Chang Claude, Jenny ^d   Drogen, Dagmar ^e   Tjonneland, Anne ^f   Overvad, Kim ^g   Quiros, J Ramon ^h   Gonzalez, Carlos A ⁱ   Sanchez, Maria Jose ^j,k   Larranaga, Nerea ^k,l   Navarro, Carmen ^k,m   Barricarte, Aurelio ^k,n   Travis, Ruth C ^o   Khaw, Kay Tee ^p   Wareham, Nick ^q   Trichopoulou, Antonia ^b,s,t   Lagiou, Pagona ^b,s,u   Trichopoulos, Dimitrios ^t,u   Peeters, Petra H M ^v   Panico, Salvatore ^x   Masala, Giovanna ^y   Grioni, Sara ^z   Tumino, Rosario ^aa   Vineis, Paolo ^r,ab   Bueno De Mesquita, H Bas ^v,w   Laurell, Goran ^ac   Hallmans, Goran ^ac   Manjer, Jonas ^ad   Ekstrom, Johanna ^ad   Skeie, Guri ^af   Lund, Eiliv ^af   Weiderpass, Elisabete ^ae,af,ag,ah   Ferrari, Pietro ^c   Byrnes, Graham ^c   Romieu, Isabelle ^c   Riboli, Elio ^r   Hildesheim, Allan ^a   Boeing, Heiner ^e   Pawlita, Michael ^d   Brennan, Paul ^c   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^f INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^g Institute of Public Health   (Denmark)

^h PHD   (Spain)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^k CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^l Basque Government   (Spain)

^m DEPARTMENT OF EPIDEMIOLOGY   (Spain)

ⁿ INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^q UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^r IMPERIAL COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^t HELLENIC HEALTH FOUNDATION   (Greece)

^u BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^x UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^y Molecular and Nutritional Epidemiology Unit Cancer   (Italy)

^z NATIONAL CANCER INSTITUTE   (Italy)

^aa CIVILE M P AREZZO HOSPITAL   (Italy)

^ab HuGeF Foundation   (Italy)

^ac UMEÅ UNIVERSITY   (Sweden)

^ad LUND UNIVERSITY HOSPITAL   (Sweden)

^ae KAROLINSKA INSTITUTE   (Sweden)

^af UNIVERSITY OF TROMSØ   (Norway)

^ag CANCER REGISTRY OF NORWAY   (Norway)

^ah FOLKHÄLSAN RESEARCH CENTER   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HUMAN PAPILLOMAVIRUS ANTIBODY; ONCOPROTEIN; PROTEIN E7; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRAL REGULATORY PROTEIN E4; VIRUS ANTIBODY; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; REPRESSOR PROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; ESOPHAGUS CANCER; EVALUATION STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 6; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MOUTH CANCER; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; WART VIRUS; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; EUROPE; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; PAPILLOMAVIRUS INFECTIONS; UNITED STATES; VIROLOGY;

ADULT; AGED; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; COHORT STUDIES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; UNITED STATES;

EID: 84883134703     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.2738     Document Type: Article

References (26)

1. Bouvard V, Baan R, Straif K, et al: A review of human carcinogens: Part B-Biological agents. Lancet Oncol 10:321-322, 2009
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
3. Näsman A, Attner P, Hammarstedt L, et al: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int J Cancer 125: 362-366, 2009
4. Hong AM, Grulich AE, Jones D, et al: Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 28:3269-3272, 2010
5. Mork J, Lie AK, Glattre E, et al: Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125-1131, 2001
6. Dillner J: The serological response to papillomaviruses. Semin Cancer Biol 9:423-430, 1999
7. Waterboer T, Sehr P, Pawlita M: Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309:200-204, 2006
8. Waterboer T, Sehr P, Michael KM, et al: Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 51:1845-1853, 2005
9. Ribeiro KB, Levi JE, Pawlita M, et al: Low human papillomavirus prevalence in head and neck cancer: Results from two large case-control studies in high-incidence regions. Int J Epidemiol 40:489-502, 2011
10. Smith EM, Rubenstein LM, Haugen TH, et al: Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: A case for multifactor disease. J Oncol 2012:571862, 2012
11. Sitas F, Egger S, Urban MI, et al. InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 104:147-158, 2012
12. Riboli E, Hunt KJ, Slimani N, et al: European Prospective Investigation Into Cancer and Nutrition (EPIC): Study populations and data collection. Public Health Nutr 5:1113-1124, 2002
13. Clifford GM, Shin HR, Oh JK, et al: Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16:1874-1879, 2007
14. Bray F: Chapter eight: Age-standardization, in Parkin DM, Whelan SL, Ferlay J, et al (eds): Cancer Incidence in Five Continents (vol VIII). Lyon, France, IARC Scientific Publications, 2002 (No. 155)
15. Zumbach K, Hoffmann M, Kahn T, et al: Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer 85:815-818, 2000
16. Smith EM, Pawlita M, Rubenstein LM, et al: Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 127:111-117, 2010
17. Herrero R, Castellsagué X, Pawlita M, et al: Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772-1783, 2003
18. Heideman DA, Waterboer T, Pawlita M, et al: Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 25:4550-4556, 2007
19. Meschede W, Zumbach K, Braspenning J, et al: Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 36:475-480, 1998
20. Zumbach K, Kisseljov F, Sacharova O, et al: Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervicalcarcinoma patients from Russia. Int J Cancer 85: 313-318, 2000
21. Silins I, Avall-Lundqvist E, Tadesse A, et al: Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol 85:333-338, 2002
22. Lehtinen M, Pawlita M, Zumbach K, et al: Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 188:49-55, 2003
23. Anderson KS, Wong J, D'Souza G, et al: Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer 104:1896-1905, 2011
24. Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-1079, 2005
25. D'Souza G, Kreimer AR, Viscidi R, et al: Casecontrol study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944-1956, 2007
26. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010